Ampio Pharmaceuticals Inc. [AMEX: AMPE] traded at a high on 08/15/22, posting a 3.18 gain after which it closed the day’ session at $0.11. The company report on August 3, 2022 that Ampio Pharmaceuticals Issues Letter to Stockholders.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
The results of the trading session contributed to over 9261110 shares changing hands. Over the past one week, the price volatility of Ampio Pharmaceuticals Inc. stands at 10.31% while the volatility over the past one month is 12.30%.
The market cap for AMPE stock reached $24.18 million, with 226.09 million shares outstanding and 209.00 million shares in the current float. Compared to the average trading volume of 5.11M shares, AMPE reached a trading volume of 9261110 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ampio Pharmaceuticals Inc. [AMPE]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMPE shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMPE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Ampio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 19, 2019. While these analysts kept the previous recommendation, Aegis Capital raised their target price from $15 to $16. The new note on the price target was released on March 17, 2014, representing the official price target for Ampio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $11, while Aegis Capital analysts kept a Buy rating on AMPE stock.
The Average True Range (ATR) for Ampio Pharmaceuticals Inc. is set at 0.01 The Price to Book ratio for the last quarter was 1.19, with the Price to Cash per share for the same quarter was set at 0.10.
How has AMPE stock performed recently?
Ampio Pharmaceuticals Inc. [AMPE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.47. With this latest performance, AMPE shares dropped by -35.50% in over the last four-week period, additionally sinking by -78.84% over the last 6 months – not to mention a drop of -92.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMPE stock in for the last two-week period is set at 35.78, with the RSI for the last a single of trading hit 34.76, and the three-weeks RSI is set at 37.39 for Ampio Pharmaceuticals Inc. [AMPE]. The present Moving Average for the last 50 days of trading for this stock 0.1631, while it was recorded at 0.1021 for the last single week of trading, and 0.4939 for the last 200 days.
Ampio Pharmaceuticals Inc. [AMPE]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -76.23, with Return on Assets sitting at -55.35.
Ampio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.80.
Insider trade positions for Ampio Pharmaceuticals Inc. [AMPE]
There are presently around $3 million, or 20.70% of AMPE stock, in the hands of institutional investors. The top three institutional holders of AMPE stocks are: VANGUARD GROUP INC with ownership of 8,291,965, which is approximately -10.909% of the company’s market cap and around 7.64% of the total institutional ownership; BLACKROCK INC., holding 4,699,064 shares of the stock with an approximate value of $0.5 million in AMPE stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $0.22 million in AMPE stock with ownership of nearly 998.59% of the company’s market capitalization.
Positions in Ampio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 36 institutional holders increased their position in Ampio Pharmaceuticals Inc. [AMEX:AMPE] by around 5,793,445 shares. Additionally, 58 investors decreased positions by around 23,976,124 shares, while 52 investors held positions by with 547,147 shares. The mentioned changes placed institutional holdings at 30,316,716 shares, according to the latest SEC report filing. AMPE stock had 19 new institutional investments in for a total of 2,407,205 shares, while 31 institutional investors sold positions of 4,582,122 shares during the same period.